Pediatric ME/CFS: Diagnosis, Management, and Prognosis

1 Rowe et al. 2017 — Pediatric ME/CFS: A Comprehensive Primer

Full Citation:: Rowe PC, Underhill RA, Friedman KJ, Gurwitt A, Medow MS, Schwartz MS, Speight N, Stewart JM, Vallings R, Rowe KS. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer. Frontiers in Pediatrics. 2017;5:121. DOI:: 10.3389/fped.2017.00121 PMID:: 28674681 PMCID:: PMC5474682 Published:: June 2017 Study Design:: Expert consensus review / clinical primer (10 co-authors; international) Key Findings::

- Paediatric recovery rates in ME/CFS range from 54–94% across studies, substantially higher than adult recovery rates of approximately 5–22%
- Earlier diagnosis and appropriate management (particularly pacing and OI treatment) are associated with improved outcomes
- Orthostatic intolerance is present in the majority of paediatric ME/CFS cases and should be identified and treated as a primary target
- Avoidance of graded exercise therapy and push-crash cycles is recommended; activity-based approaches can worsen prognosis
- School re-integration should follow clinical improvement rather than be used to drive recovery

Relevance to ME/CFS:: Primary clinical reference for paediatric ME/CFS management. The recovery rate data (54–94%) are cited throughout the document to contrast with adult outcomes and support the developmental recovery hypotheses (glial maturation window, immune memory pruning, HSC exhaustion). The OI treatment emphasis directly informs the OI-as-lynchpin model. Certainty Assessment::

- *Quality:* Medium-High (Frontiers in Pediatrics; expert consensus from international panel)
- *Study type:* Clinical review / expert consensus primer; no systematic review methodology
- *Limitations:* Recovery rate range (54–94%) reflects heterogeneous studies with different diagnostic criteria, severity definitions, and follow-up periods
- *Authority:* Co-authored by Rowe PC (leading paediatric OI researcher) and Rowe KS (leading paediatric ME/CFS outcomes researcher)

2 Rowe 2019 — Long-Term Follow-Up of Young People with CFS

Full Citation:: Rowe KS. Long Term Follow up of Young People with Chronic Fatigue Syndrome Attending a Pediatric Outpatient Service. Frontiers in Pediatrics. 2019;7:21. DOI:: 10.3389/fped.2019.00021 PMID:: 30805319 PMCID:: PMC6393360 Published:: February 2019 Study Design:: Retrospective longitudinal cohort study Key Findings::

- Long-term follow-up of a paediatric ME/CFS cohort from a specialist outpatient service confirms substantial proportions of paediatric patients achieve functional recovery
- Recovery was genuine and sustained, not merely symptomatic accommodation; patients returned to schooling, employment, and social function
- Duration to recovery varied widely; recovery continued to occur years after onset in some patients
- Severity at presentation and presence of comorbidities influenced prognosis; OI identification and treatment associated with more favorable trajectories

Relevance to ME/CFS:: Provides longitudinal clinical evidence for the paediatric recovery advantage underpinning multiple developmental hypotheses in the document. Establishes that the 54–94% recovery rates cited in the 2017 primer reflect genuine functional recovery. Confirms that management approach modulates outcome. Certainty Assessment::

- *Quality:* Medium (Frontiers in Pediatrics; Rowe KS is a leading authority in paediatric ME/CFS)
- *Study type:* Retrospective cohort; single centre (Melbourne, Australia)
- *Limitations:* Single-centre; selection bias toward specialist-referred patients; recovery defined by clinical assessment without standardized objective instruments; some patients lost to follow-up

3 van Campen et al. 2020 — Severity Validation by Objective Measures

Full Citation:: van Campen CLM, Rowe PC, Visser FC. Validation of the Severity of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome by Other Measures than History: Activity Bracelet, Cardiopulmonary Exercise Testing and a Validated Activity Questionnaire: SF-36. Healthcare. 2020;8(3):273. DOI:: 10.3390/healthcare8030273 PMID:: 32823715 PMCID:: PMC7551321 Published:: August 2020 Study Design:: Cross-sectional validation study Key Findings::

- Clinician-assessed severity levels in ME/CFS correlate significantly with three independent objective measures: (1) daily step counts from actigraphy bracelets, (2) peak VO~2~ on cardiopulmonary exercise testing (CPET), (3) SF-36 physical functioning and social role subscores
- Patients in the most severe clinical categories demonstrated markedly reduced step counts, impaired CPET performance, and severely depressed SF-36 scores
- Objective measurements independently confirmed clinical severity classifications, validating clinician-based severity staging as a reliable tool
- Supports the use of distinguishable functional severity tiers corresponding to measurable differences in physical capacity

Relevance to ME/CFS:: Provides objective validation for the severity-stratified care approach (Section Severity-Stratified Care Pathways). Demonstrates that the clinical severity tiers used in the four-tier care pathway correspond to measurable, reproducible differences in physical capacity, addressing the criticism that ME/CFS severity is purely subjective. Certainty Assessment::

- *Quality:* Medium (Healthcare/MDPI; van Campen and Visser are established ME/CFS researchers; Rowe PC adds international credibility)
- *Study type:* Cross-sectional validation study; single centre (Netherlands)
- *Limitations:* CPET may underrepresent most severe patients who cannot exercise; severity thresholds may require population-specific adjustment

4 Jahanbani et al. 2024 — Extremely Severe ME/CFS Longitudinal Case Study

Full Citation:: Jahanbani F, Sing J, Maynard RD, et al. Longitudinal cytokine and multi-modal health data of an extremely severe ME/CFS patient with HSD reveals insights into immunopathology, and disease severity. Frontiers in Immunology. 2024;15:1369295. DOI:: 10.3389/fimmu.2024.1369295 Published:: 2024 Study Design:: Longitudinal single-patient deep phenotyping case study Key Findings::

- Proposed extended severity classification subdividing the very severe range into five extremely severe sub-levels (A through E), with E representing the most profound disability
- Demonstrated that patients beyond traditional "very severe" exhibit clinically meaningful differences in functional capacity: ability to communicate, tolerate sensory input, or take nutrition orally
- Longitudinal cytokine profiling revealed immunopathological signatures that varied with severity sub-level transitions
- Multi-modal health data (cytokines, clinical assessments, functional measures) captured disease evolution at the extreme end of the spectrum that standard four-level scales cannot resolve
- The patient's trajectory through sub-levels illustrated that recovery at the extremely severe end produces minimal perceptible improvement despite ongoing biological changes

Relevance to ME/CFS:: Provides the first systematic framework for classifying extremely severe ME/CFS beyond the standard mild/moderate/severe/very-severe categories. The extended A–E sub-classification is integrated into the ratchet model’s severity mapping (Section Disease Progression Models, Equation ratchet severity extended). The observation that equal functional gains produce diminishing clinical visibility at lower severity is explained by the model’s emergent recovery asymmetry (Equation recovery scaling) without requiring an extrinsic nonlinear mapping. Certainty Assessment::

- *Quality:* Medium (Frontiers in Immunology; established ME/CFS research group including R.\ W.\ Davis)
- *Study type:* Single-patient longitudinal case study; deep phenotyping with multi-modal data
- *Limitations:* $n = 1$; severity sub-level thresholds not validated in cohort study; HSD comorbidity may confound some findings; replication of the classification framework in larger cohorts needed

5 Moore et al. 2023 — Recovery from Exercise in ME/CFS

Full Citation:: Moore GE, Keller BA, Stevens J, et al. Recovery from Exercise in Persons with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Medicina. 2023;59(3):571. DOI:: 10.3390/medicina59030571 PMID:: 36984572 Published:: March 2023 Study Design:: Prospective cohort study with 2-day CPET protocol Sample Size:: \(n = 78\) ME/CFS, \(n = 64\) sedentary controls Key Findings::

- ME/CFS subjects required mean $ 12.7 \pm 1.2$ days to recover post-CPET versus $ 2.1 \pm 0.2$ days for controls ($p < 0.0001$)
- Recovery range in ME/CFS: 1--64 days; approximately 7--8% required 1--2 months; one subject did not recover after one year
- Pharmacokinetic modeling confirmed extremely prolonged decay of PEM response
- *Critical null result:* no significant difference in recovery time across ME/CFS baseline symptom severity levels ($F = 1.12$, $p = 0.33$)

Relevance to ME/CFS:: The null severity–recovery-time result constrains interpretation of the piecewise recovery scaling prediction (Equation recovery scaling, Table Disease Progression Models). The prediction applies to within-person dynamics (how recovery time changes as a single patient’s \(B\) evolves), not between-person cross-sectional comparisons where inter-individual parameter variation dominates. Additionally, CPET exclusion of the most severe patients truncates the severity range over which the scaling would be most pronounced. Certainty Assessment::

- *Quality:* High (standardized 2-day CPET protocol, Canadian Consensus Criteria)
- *Study type:* Prospective cohort; moderate sample size
- *Limitations:* Post-CPET activity not monitored; SSS forms collected only through day 10; exclusion of one non-recovering subject; severity measured by self-reported symptom burden rather than objective functional grading

6 Sommerfelt, Schei & Angelsen 2023 — Severe and Very Severe ME/CFS in Norway

Full Citation:: Sommerfelt K, Schei T, Angelsen A. Severe and Very Severe Myalgic Encephalopathy/Chronic Fatigue Syndrome ME/CFS in Norway: Symptom Burden and Access to Care. Journal of Clinical Medicine. 2023;12(4):1487. DOI:: 10.3390/jcm12041487 PMID:: 36836022 Published:: February 2023 Study Design:: Cross-sectional survey Sample Size:: \(n = 586\) (47 very severe, 444 severe, 95 severe-moderate) Key Findings::

- Among very severe patients: 17% tube-fed, 43% had swallowing problems, 60% could not tolerate normal speech volume, 77% could not tolerate indoor lighting
- 46 of 47 very severe patients never left the house; 76% never had visitors
- Provides the most granular empirical characterisation of functional capacity at the extreme end currently available in peer-reviewed literature
- Demonstrates enormous heterogeneity within the "very severe" category, supporting finer-grained sub-classification

Relevance to ME/CFS:: The functional milestone data (tube feeding, sensory tolerance, communication capacity) provide candidate anchors for calibrating the extremely severe sub-level thresholds (\(\theta_\text{es}\) and band width \(w\)) in the extended ratchet severity model (Equation ratchet severity extended). Certainty Assessment::

- *Quality:* Medium (large survey, peer-reviewed JCM)
- *Study type:* Internet-based survey; self-reported diagnosis
- *Limitations:* Selection bias toward patients who can access internet; proxy-reported data for most severe patients; standard four-tier ICC classification used (no additional sub-levels proposed)

7 Sommerfelt et al. 2024 — FUNCAP Functional Capacity Questionnaire

Full Citation:: Sommerfelt K, Schei T, Seton KA, Carding SR. Assessing Functional Capacity in Myalgic Encephalopathy/Chronic Fatigue Syndrome: A Patient-Informed Questionnaire. Journal of Clinical Medicine. 2024;13(12):3486. DOI:: 10.3390/jcm13123486 PMID:: 38930014 Published:: June 2024 Study Design:: Instrument development and validation study (6-round iterative) Sample Size:: \(n = 1{,}263\) Norwegian + \(n = 1{,}387\) international validation Key Findings::

- Developed FUNCAP55 and FUNCAP27---the first ME/CFS-specific functional capacity instrument designed to avoid floor and ceiling effects across the full severity spectrum
- Eight functional domains including light/sound sensitivity and basic functions (washing, eating)
- Negligible floor/ceiling effects in both cohorts, including very severe patients
- Test-retest reliability validated ($n = 301$)
- Authors explicitly state FUNCAP captures capacity "in both mild and very severe ME/CFS patients"

Relevance to ME/CFS:: FUNCAP addresses the measurement gap that limits validation of the extended severity classification. Generic instruments (SF-36, Karnofsky) exhibit severe floor effects at the extremely severe end, making longitudinal tracking of within-person recovery impossible. FUNCAP’s sensitivity across the full spectrum is a prerequisite for empirical testing of the piecewise recovery scaling prediction (Equation recovery scaling, Table Disease Progression Models). Certainty Assessment::

- *Quality:* High (large samples, iterative validation, test-retest)
- *Study type:* Instrument development; psychometric validation
- *Limitations:* Self-reported diagnosis without medical record verification; proxy-response bias for most severe patients; no comparison against objective functional measures (actigraphy, CPET)

8 Heng et al. 2025 — Mapping the Complexity of ME/CFS

Full Citation:: Heng RB, Gunasegaran B, Krishnamurthy S, et al. Mapping the complexity of ME/CFS: Evidence for abnormal energy metabolism, altered immune profile, and vascular dysfunction. Cell Reports Medicine. 2025;6(12):102514. DOI:: 10.1016/j.xcrm.2025.102514 Published:: December 2025 Study Design:: Multi-omics cohort study Key Findings::

- Multi-modal investigation providing convergent evidence for three core pathophysiological domains: (1) abnormal energy metabolism, (2) altered immune profile, (3) vascular dysfunction
- Metabolic abnormalities included altered tryptophan metabolism and impaired oxidative phosphorylation consistent with mitochondrial dysfunction
- Immune alterations were detected across both innate and adaptive compartments
- Vascular dysfunction objectively documented, supporting the OI-lynchpin model and cardiovascular pathophysiology described in the integrative models chapter

Relevance to ME/CFS:: High-quality recent cohort study providing multi-omic validation of the integrative framework used throughout the document. The three-domain structure (energy, immune, vascular) maps directly onto the septad model. Certainty Assessment::

- *Quality:* High (Cell Reports Medicine; Cell Press journal; peer-reviewed)
- *Study type:* Cohort study with multi-omics; cross-sectional
- *Limitations:* December 2025 publication — very recent; independent replication pending